medikinet cr (medikinet retard) hart hylki með breyttan losunarhraða 60 mg
medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 60 mg
medikinet tafla 10 mg
medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - tafla - 10 mg
medikinet tafla 20 mg
medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - tafla - 20 mg
medikinet tafla 5 mg
medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - tafla - 5 mg
paracetamol medical valley filmuhúðuð tafla 1 g
medical valley invest ab - paracetamolum inn - filmuhúðuð tafla - 1 g
paracetamol medical valley filmuhúðuð tafla 500 mg
medical valley invest ab - paracetamolum inn - filmuhúðuð tafla - 500 mg
febuxostat medical valley filmuhúðuð tafla 80 mg
medical valley invest ab - febuxostatum inn - filmuhúðuð tafla - 80 mg
zoledronic acid medac
medac gesellschaft für klinische spezialpräparate mbh - zoledronsýru einhýdrat - fractures, bone; cancer - lyf til að meðhöndla beinsjúkdóma - forvarnir vegna tengdra beinagrindar (sjúkdómsbrot, mænuþrýstingur, geislun eða skurðaðgerð í bein eða æxlisfrumna blóðkalsíumhækkun) hjá fullorðnum sjúklingum með langt gengið illkynja sjúkdóma sem fela í sér bein. meðferð fullorðinn sjúklinga með æxli völdum álíka (tih).
bcg-medac duft og leysir fyrir þvagblöðrudreifu
medac gesellschaft für klinische spezialpräparate gmbh - bcg bacteria - duft og leysir fyrir þvagblöðrudreifu
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - Æxlishemjandi lyf - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).